EGFR-targeted intraoperative fluorescence imaging detects high-grade glioma with panitumumab-IRDye800 in a phase 1 clinical trial
Quan Zhou, Nynke S. van den Berg, Eben L. Rosenthal, Michael Iv, Michael Zhang, Johana C. M. Vega Leonel, Shannon Walters, Naoki Nishio, Monica Granucci, Roan C. Raymundo, Grace Yi, Hannes Vogel, Romain Cayrol, Y.-J. Lee, Guolan Lu, Marisa E. Hom, Wenying Kang, Melanie Hayden Gephart, Larry D. Recht, Seema Nagpal, Reena Thomas, Chirag B. Patel, Gerald A. Grant, Gordon Li
Abstract
: Panitumumab-IRDye800 provided excellent tumor contrast and was safe at both doses. Smaller fragments of tumor could be detected at the 100 mg dose and thus more suitable for intraoperative imaging.
Topics & Concepts
PanitumumabGliomaMedicineFluorescence-lifetime imaging microscopyFluorescenceCancer researchInternal medicineColorectal cancerCancerKRASPhysicsOpticsGlioma Diagnosis and TreatmentNanoplatforms for cancer theranosticsCancer, Hypoxia, and Metabolism